Marlborough drugmaker RXi Pharmaceuticals is set to receive nearly $250,000 in grant funds for a collaboration with Cambridge-based BioAxone BioSciences.
The companies last month jointly announced grant funding from the National Institute of Neurological Disorders and Stroke to develop a drug to treat spinal cord injuries.
The total grant is worth nearly $1.8 million, with the majority going to BioAxone. RXi was awarded about $129,000 last year and will receive $118,800 this year for its contributions.
The pre-clinical drug BA-434, using RXi’s therapeutic platform, is designed to regenerate neurons in the nervous system after neurotrauma.
